Chronic Obstructive Pulmonary Disease

Obtain spirometry after an adequate dose of at least one short-acting inhaled bronchodilator. A post-bronchodilator FEV₁/FVC ratio <0.70 supports COPD; complete absence of bronchodilator reversibility is neither necessary nor typical. Grade obstruction by post-bronchodilator FEV₁: GOLD 1, ≥80% predicted; GOLD 2, 50% to <80%; GOLD 3, 30% to <50%; and GOLD 4, <30%. BMJ+1BMJChronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice USBMJChronic obstructive pulmonary disease (COPD) - Criteria | BMJ Best Practice

Separate physiologic severity from current clinical risk. Record CAT or mMRC, prior-year treated exacerbations and hospitalizations, smoking status and other inhalational exposures, resting and exertional oxygenation when clinically indicated, BMI or weight trajectory, comorbidity burden, and the current inhaler regimen including actual use. GOLD ABE assigns Group A to low symptoms with 0–1 nonhospitalized exacerbation, Group B to higher symptoms with 0–1 nonhospitalized exacerbation, and Group E to ≥2 exacerbations or ≥1 hospitalization regardless of symptoms. BMJ+1BMJChronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice USBMJChronic obstructive pulmonary disease (COPD) - Criteria | BMJ Best Practice

Misdiagnosis is clinically consequential because diagnostic errors often arise from spirometry technique or interpretation, primary-care assessment, diagnostic thresholds, and alternative diagnoses. Reassess patients with discordant symptom burden, imaging, exposure history, or spirometry before indefinitely intensifying COPD medications. ScienceDirectScienceDirectCauses of misdiagnosis of chronic obstructive pulmonary disease: A systematic scoping review

Long-acting bronchodilation is central to maintenance treatment. Tiotropium, a long-acting muscarinic antagonist (LAMA), is labeled for once-daily COPD maintenance and exacerbation reduction at two 2.5-mcg inhalations once daily (total 5 mcg). It is not a rescue medication; treat acute bronchospasm with a rapid-acting beta₂-agonist. In placebo-controlled trials, tiotropium reduced exacerbation rates and delayed time to first exacerbation. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT. SPIRIVA® RESPIMAT® (tiotropium bromide inhalation spray), for oral inhalation use Initial U.S. Approval: 2004

Before changing medication, directly observe device use and determine whether the prescribed device matches inspiratory capacity, dexterity, cognition, visual function, and cost/access. Persistent symptoms may reflect incorrect delivery, undertreatment, deconditioning, cardiac disease, anemia, obesity, sleep-disordered breathing, pulmonary vascular disease, or another diagnosis rather than insufficient bronchodilation. BMJ+1BMJChronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice USScienceDirectCauses of misdiagnosis of chronic obstructive pulmonary disease: A systematic scoping review

ICS-containing therapy is an exacerbation-prevention strategy, not a substitute for bronchodilator optimization. Blood eosinophils estimate the likelihood of benefit: evidence summarized in GOLD indicates little or no ICS effect below 100 cells/µL and maximal effect at ≥300 cells/µL. In COPD, ICS-containing fluticasone furoate/vilanterol increased pneumonia incidence versus vilanterol alone in replicate 12-month trials (6% with 100/25 mcg vs 3% with vilanterol); monitor for pneumonia because clinical features overlap with exacerbation. BMJ+1BMJChronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice USaccessdata fda[PDF] breo ellipta - accessdata.fda.gov

Ensifentrine is an inhaled dual PDE3/PDE4 inhibitor labeled for maintenance treatment of COPD in adults. The labeled dose is 3 mg by standard jet nebulizer with mouthpiece twice daily, using one unit-dose ampule each morning and evening; do not physically mix it with other nebulized medications because compatibility has not been established. fdafdahighlights of prescribing information

In ENHANCE-1 and ENHANCE-2, ensifentrine improved Week-12 FEV₁ AUC₀–12h versus placebo by 87 mL and 94 mL, respectively. The trials enrolled patients with moderate-to-severe COPD, and many received concurrent LAMA, LABA, or LABA/ICS therapy; therefore, the evidence supports use alongside existing maintenance bronchodilator regimens in selected patients rather than as an acute bronchodilator. fdafdahighlights of prescribing information

Smoking cessation remains the central exposure-targeted intervention. At every visit, document tobacco status and cessation treatment; also assess occupational, biomass, and other inhalational exposures. Vaccination, physical activity, nutrition, pulmonary rehabilitation, and optimization of cardiovascular and mental-health comorbidity should be integrated with inhaled treatment rather than deferred until advanced disease. Current COPD guidance includes GOLD 2025, ATS pulmonary rehabilitation guidance, and VA/DoD COPD guidance. BMJBMJChronic obstructive pulmonary disease (COPD) - Guidelines | BMJ Best Practice US

Refer appropriate patients to pulmonary rehabilitation for exercise intolerance, activity limitation, post-exacerbation functional loss, or deconditioning. Objective exercise assessment can clarify disproportionate dyspnea and help select patients for rehabilitation. BMJ+1BMJChronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice USBMJChronic obstructive pulmonary disease (COPD) - Guidelines | BMJ Best Practice US

At follow-up, do not use FEV₁ alone as a marker of therapeutic success. Reassess CAT or mMRC, exacerbation frequency and care setting, rescue use, device technique, adverse effects, tobacco exposure, oxygenation when indicated, body weight, and treatment burden. New frequent rescue use or declining rescue response should trigger urgent reassessment for deterioration, alternative diagnoses, and a revised plan. accessdata fda+1accessdata fda[PDF] breo ellipta - accessdata.fda.govdailymed nlm nihDailyMed - PERFOROMIST- formoterol fumarate dihydrate solution